Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cryo-FIRST: Cryoprecipitate For Immediate Resuscitation in Severe Trauma: Effectiveness of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) for Treatment of Trauma Associated Hemorrhage

NCT07218185 is registered in ClinicalTrials.gov with Cerus Corporation as lead sponsor.

NCT NCT07218185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cryo-FIRST: Cryoprecipitate For Immediate Resuscitation in Severe Trauma: Effectiveness of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) for Treatment of Trauma Associated Hemorrhage
Lead sponsor
Cerus Corporation
Phase
Observational
Overall status
Enrolling by invitation
Start date
September 15, 2026
Completion date
August 31, 2028
Enrollment
320 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhage, hemorrhagic shock, hypofibrinogenemia, trauma associated hemorrhage